Main idea: The meta-analysis demonstrated the positive clinical improvements which triamcinolone acetonide has on total ocular allergy symptoms, especially on tearing, in addition to its recognized nasal symptom efficacy in seasonal allergic rhinitis.
Allergic rhinitis is a prevalent disease, which can be classed as seasonal (SAR) or perennial. In addition to nasal symptoms, up to 75% of sufferers experience itching, redness, and tearing of the eyes. Intranasal corticosteroids are effective in controlling allergic nasal symptoms. Iincreasing evidence suggest that they also can relieve some of the allergic ocular symptoms.
The objective of the study was to evaluate the magnitude of the efficacy of triamcinolone acetonide (TAA) compared with placebo or fluticasone propionate (FP) on ocular symptom improvement in patients with seasonal allergic rhinitis. A meta-analysis of summary data from 8 randomized, double- or single-blind trials, assessing average change in total or individual (tearing, redness, and itching) eye symptoms was conducted.
Results: Total eye symptom reduction after 2 weeks was greater with triamcinolone acetonide than with placebo. An average treatment difference was -0.32. In addition, significant reductions in tearing, but no itching or redness, were observed after triamcinolone acetonide treatment compared with placebo. No significant treatment difference was seen between triamcinolone acetonide and fluticasone propionate in total ocular symptoms at any of the time points measured (weeks 1, 2, 3, and overall). All treatments exhibited similar safety profiles and were deemed well tolerated.